Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07216248 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

Study acronym: OPTIMAS
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 7 words Secondary endpoints: details revised at 6 of 19 entriesv3 Show 1 more changeShow less
    • Secondary endpoints: details revised at 6 of 19 entries

    See this version in full on ClinicalTrials.gov ↗

  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Oct 2025 to Oct 27, 2025 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Oct 2025 to Oct 27, 2025
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate intermittent relugolix + androgen receptor pathway inhibitor (ARPI) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.
Trial Details
NCT Number NCT07216248
Lead Sponsor University of Utah
Conditions Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov